BioFit - Fostering Innovation & Transfer - Conference
01-12-2020 - 09:00 - 02-12-2020 - 17:00
Palais de la Musique et des Congrès
Place de Bordeaux
67082 - STRASBOURG
With the highest attending rate of academics, TTOs and research institutions, BioFIT is the place where academia-industry collaborations get started. BioFIT has taken on a whole new dimension becoming the meeting point in Europe for tech transfer and for sourcing early-stage innovations stemming from public research institutions, academic spin-offs and emerging biotech companies. Together with big pharma, biotech and diagnostic companies, BioFIT operates as a platform to build partnerships for all public and private actors. BioFIT is also the European marketplace for pre-seed, seed and Series A investment in Life Sciences.
What BioFIT features
- Pre-qualified one-to-one meetings leveraging the partnering system developed by Inova software and used at the BIO International Convention.
- Conferences and roundtable discussions
- Presentations of start-ups
- Presentations of collaborative and licensing opportunities
- An exhibition area
- Identification of would-be CEOs Are you a bioentrepreneur seeking a project? Or do you have projects needing a CEO? Attend BioFIT by using the partnering platform and identify your future project or your future CEO.
- Informal networking evenings
Steered by a prestigious Committee, the BioFIT conference programme brings together bright minds to debate on innovation-focused topics, to foster learning, inspiration and conversations that matter.
Over 80 international experts will discuss current stakes of the sector related to innovative academia-industry collaborations, early-stage assets and investment.
WHY ATTEND BIOFIT?
Out of 1,200 BioFIT attendees, 1,000 deals have been generated. The breakdown in terms of nature of deals is the following:
- 35%of collaborative research projects
- 30%of licensing deals
- 15%of equity investment deals
- 20%of services deals
Estimate based on the measurement of 2017 and 2018 delegates’ outcomes
- 900+ organisations
- 35+countries represented
- 1,000deals generated in 2018
- Pharma: Almirall | Astellas Pharma | Bayer | Boehringer Ingelheim | GSK | Ipsen Innovation | Kyowa Kirin Pharmaceutical | Lilly | Maruho Co | Merck | MSD | Novo Nordisk | Pfizer | Roche | Sanofi | Servier | Thea Open Innovation…
- Veterinary: Bayer Animal Health | Boehringer Ingelheim Animal Health | Ceva Animal Health | MSD Animal Health | Vetoquinol | Virbac | Zoetis...
- Biotech and Diag: Evotec | Genfit | Innate Pharma | LFB | Syngulon…
- TTOs and academia: Ascenion | CNRS | EMBLEM | INRA | Inserm Transfert | King’s College | LifeArc | Max Planck Institute | NIH | Oxford University | Princeton University | Technion | TNO | Yissum...
- Investors (pre-seed, seed, Series A): Abingworth | Advent France Biotechnology Asabys Partners | BioGeneration VenturesEarlybird Europen Investment Bank | Fournier-Majoie Foundation Hadean Ventures | High-Tech Gründerfonds Kurma Partners | Medicxi | M Ventures | Novo Seeds Seventure Partners | Sofinnova Partners | Theodorus Turenne Capital...
Please check out the different participants’ lists of the previous editions, as well as the list of last year’s edition >>here<<.
Discounts always apply on the “regular fee” except during the “late registration” period. Discount cannot be combined with any other offer.
How to grow a successful early-stage partnership with pharma?
What is pharma awaiting from start-up which with they would like to interact? Learn from success stories of pharma-biotech collaborations through successful deals they made. What were the hurdles to these deals? What are the keys to carry a good partnership? What are the factors of success and of influence? Learn from figures and statistics: how many people get a deal at the end? How to picture your invention in the best possible way to make a deal? How interactions between early-stage projects and pharma help anticipate pitfalls at the very early development stages?
When addressing academia-industry relationships, the academic scientist may argue that the private sector sponsored research is at the cost of basic science and academic freedom. Yet, misalignment of the scientific value for a given research program opposed to its actual market is a constant mistake made by scientists. What are considered “mistakes” respectively in the industry and in the academia languages? This session advocates that a problem shared is a problem solved.
Fostering academia-industry partnerships is key to fuel innovation in the sector. Which sectors are prone to fuel collaborations? What are the elements to forgather to merge the scientific, academic, advocacy and industry spheres? How are the advances in specific fields influencing academia-pharma partnerships? How can these collective efforts question the way the industry is covering the pre-competitive status?
Early-stage assets evolve in an ecosystem where TTOs, scientists and entrepreneurs are closely connected. Understanding the mechanisms and difficulties of nurturing and licensing assets is key to properly influence the valuation of assets at an early stage. How can we fully understand the proposition behind the value? How can we transform science into business more frequently and efficiently?
This track aims to understand the mechanisms enforcing investors’ presence in early stages of development. Are we witnessing surges of investment in specific therapeutic areas? Who are the new players involved in investing on the biotech sector and what are their pre-requisites? Are there increasing interactions and partnerships between pharma and VCs at these initial stages?
BioFit contact: Margaux SATOLA, Business Development Manager, firstname.lastname@example.org, +33 (0)3 59 39 01 82